OXFD - オックスフォ―ド・イミュノテック・グロ―バル (Oxford Immunotec Global PLC) オックスフォ―ド・イミュノテック・グロ―バル

 OXFDのチャート


 OXFDの企業情報

symbol OXFD
会社名 Oxford Immunotec Global Plc (オックスフォ―ド・イミュノテック・グロ―バル)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 オックスフォード・イムノテック・グローバル(Oxford Immunotec Global PLC)は診断会社である。同社は主に、不十分な免疫調節状態の試験を開発、商品化する。同社の製品ライン及び開発活動は、主に感染症、移植、自己免疫と炎症性疾患および免疫腫瘍学の4つの分野に焦点を当てる。T-SPOT.TB検査は、免疫調節された状態の患者の診断、予後およびモニタリングを知らせるために特定の免疫細胞の応答を測定することを可能にする結核(TB)検査、感染検査、T-SPOT技術プラットフォームである。同社はイムゲンと免疫学の買収により得られたライム病などのダニ媒介疾患のアッセイを提供する。同社にはダニ媒介性疾患の専門知識を基に、血液スクリーニングに使用するための一連のアッセイがある。T-SPOT. CMVとT-SPOT. PRT検査は、移植市場に特化した製品ラインの一部である。   オックスフォ―ド・イミュノテック・グロ―バルは英国の医療診断会社。独自の結核菌感染検査「T-スポット」技術に基づき、疾病の試験薬・キットを開発する。ELISA法を使用した結核補助診断キット同社の「T-スポット.TB」検査は、米国、一部欧州、および日本で直接販売され、その他市場では販売業者を通じて販売されている。   
本社所在地 94C Innovation Drive Milton Park Abingdon OX14 4RZ GBR
代表者氏名 Richard A. Sandberg リチャード・A・サンドバーグ
代表者役職名 Independent Chairman of the Board
電話番号 +44 1235-44-2780
設立年月日 2013年
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 457人
url www.oxfordimmunotec.com
nasdaq_url https://www.nasdaq.com/symbol/oxfd
adr_tso
EBITDA EBITDA(百万ドル) -18.19400
終値(lastsale) 16.19
時価総額(marketcap) 420415719.23
時価総額 時価総額(百万ドル) 413.92380
売上高 売上高(百万ドル) 106.14300
企業価値(EV) 企業価値(EV)(百万ドル) 377.89080
当期純利益 当期純利益(百万ドル) -3.44400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Oxford Immunotec Global PLC revenues increased 6% to $50.7M. Net loss decreased 32% to $16.8M. Revenues reflect United States segment increase of 5% to $31.1M Asia segment increase of 6% to $15.1M. Lower net loss reflects Settlement expense decrease of 82% to $1.8M (expense) General and administrative decrease of 6% to $12.6M (expense).

 OXFDのテクニカル分析


 OXFDのニュース

   PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC - Stocks News Feed  2021/03/09 13:00:00 Stocks News Feed
WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. “Oxford Immunotec’s global role in fighting tuberculosis, particularly… Read More »PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
   SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Oxford Immunotec Global PLC - OXFD  2021/01/21 20:29:00 PR Newswire
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is…
   OXFORD IMMUNOTEC INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD  2021/01/14 00:20:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oxford Immunotec Global PLC (NasdaqGS: OXFD) to PerkinElmer, Inc. (NYSE: PKI). Under the terms of the proposed transaction, shareholders of Oxford will receive only $22.00 in cash for each share of Oxford that they own. KSF is seeking to determine whether this consideration and the process that led to it are a
   The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue  2021/01/12 13:15:54 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X Genomics Inc (NASDAQ: TXG ) AbbVie Inc (NYSE: (ABBV) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) (reacted to the company's preliminary fourth-quarter results) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Biodesix Inc (NASDAQ: BDSX ) C4 Therapeutics Inc (NASDAQ: CCCC ) CareDx Inc (NASDAQ: CDNA ) (announced preliminary fourth-quarter results) Celsius Holdings, Inc. (NASDAQ: CELH ) Chimerix Inc (NASDAQ: CMRX ) Curis, Inc. (NASDAQ: CRIS ) Dyne Therapeutics Inc (NASDAQ: DYN ) (announced positive preclinical data from its myotonic dystrophy type 1 program) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive data from midphase study of its investigational asset in treating early symptomatic Alzheimer's) ESSA Pharma Inc (NASDAQ: EPIX ) EXACT Sciences Corporation (NASDAQ: EXAS ) (reacted to preliminary fourth-quarter results) Eyenovia Inc (NASDAQ: EYEN ) Guardant Health Inc (NASDAQ: GH ) Johnson & Johnson (NYSE: JNJ ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Oxford Immunotec Global PLC (NASDAQ: OXFD ) Pacira Biosciences Inc (NASDAQ: PCRX ) Supernus Pharmaceuticals Inc (NASDAQ: SUPN ) Syneos Health Inc (NASDAQ: SYNH ) Theratechnologies Inc (NASDAQ: THTX ) Twist Bioscience Corp (NASDAQ: TWST ) United Therapeutics Corporation (NASDAQ: UTHR ) Vascular Biogenics Ltd (NASDAQ: VBLT ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan.
   Oxford Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Oxford Immunotec Global PLC Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – OXFD  2021/01/07 21:58:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether Oxford Immunotec Global PLC (NASDAQ: OXFD) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Oxford to PerkinElmer, Inc. for $22.00 in cash per share. On behalf of Oxford shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and infor
   PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC - Stocks News Feed  2021/03/09 13:00:00 Stocks News Feed
WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. “Oxford Immunotec’s global role in fighting tuberculosis, particularly… Read More »PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
   SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Oxford Immunotec Global PLC - OXFD  2021/01/21 20:29:00 PR Newswire
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is…
   OXFORD IMMUNOTEC INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD  2021/01/14 00:20:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oxford Immunotec Global PLC (NasdaqGS: OXFD) to PerkinElmer, Inc. (NYSE: PKI). Under the terms of the proposed transaction, shareholders of Oxford will receive only $22.00 in cash for each share of Oxford that they own. KSF is seeking to determine whether this consideration and the process that led to it are a
   The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue  2021/01/12 13:15:54 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X Genomics Inc (NASDAQ: TXG ) AbbVie Inc (NYSE: (ABBV) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) (reacted to the company's preliminary fourth-quarter results) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Biodesix Inc (NASDAQ: BDSX ) C4 Therapeutics Inc (NASDAQ: CCCC ) CareDx Inc (NASDAQ: CDNA ) (announced preliminary fourth-quarter results) Celsius Holdings, Inc. (NASDAQ: CELH ) Chimerix Inc (NASDAQ: CMRX ) Curis, Inc. (NASDAQ: CRIS ) Dyne Therapeutics Inc (NASDAQ: DYN ) (announced positive preclinical data from its myotonic dystrophy type 1 program) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive data from midphase study of its investigational asset in treating early symptomatic Alzheimer's) ESSA Pharma Inc (NASDAQ: EPIX ) EXACT Sciences Corporation (NASDAQ: EXAS ) (reacted to preliminary fourth-quarter results) Eyenovia Inc (NASDAQ: EYEN ) Guardant Health Inc (NASDAQ: GH ) Johnson & Johnson (NYSE: JNJ ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Oxford Immunotec Global PLC (NASDAQ: OXFD ) Pacira Biosciences Inc (NASDAQ: PCRX ) Supernus Pharmaceuticals Inc (NASDAQ: SUPN ) Syneos Health Inc (NASDAQ: SYNH ) Theratechnologies Inc (NASDAQ: THTX ) Twist Bioscience Corp (NASDAQ: TWST ) United Therapeutics Corporation (NASDAQ: UTHR ) Vascular Biogenics Ltd (NASDAQ: VBLT ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan.
   Oxford Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Oxford Immunotec Global PLC Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – OXFD  2021/01/07 21:58:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether Oxford Immunotec Global PLC (NASDAQ: OXFD) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Oxford to PerkinElmer, Inc. for $22.00 in cash per share. On behalf of Oxford shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and infor

 関連キーワード  (先端医療機器_テクノロジ― 米国株 オックスフォ―ド・イミュノテック・グロ―バル OXFD Oxford Immunotec Global PLC)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)